Integrase inhibitors: A clinical review of raltegravir and elvitegravir

Journal of HIV Therapy

Volumn 13, Issue 2, 2008, Pages 36-39

  Grant, Philip M ^a   Zolopa, Andrew ^a  

^a STANFORD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; ATAZANAVIR; DARUNAVIR; EFAVIRENZ; ELVITEGRAVIR; ENFUVIRTIDE; GS 1830105; INTEGRASE; LAMIVUDINE; NEVIRAPINE; PHENOBARBITAL; PHENYTOIN; PLACEBO; PROTEINASE INHIBITOR; RALTEGRAVIR; RIFABUTIN; RIFAMPICIN; RNA DIRECTED DNA POLYMERASE INHIBITOR; TENOFOVIR; TIPRANAVIR; UNCLASSIFIED DRUG;

ABNORMAL DREAMING; ANTIVIRAL ACTIVITY; CD4 LYMPHOCYTE COUNT; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CREATINE KINASE BLOOD LEVEL; DRUG ANTAGONISM; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG ERUPTION; DRUG METABOLISM; DRUG POTENCY; DRUG POTENTIATION; DRUG RESPONSE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERICUM PERFORATUM; INJECTION SITE REACTION; LIVER TOXICITY; NEOPLASM; NIGHTMARE; RETROVIRUS; REVIEW; SIDE EFFECT; TRIACYLGLYCEROL BLOOD LEVEL; UNSPECIFIED SIDE EFFECT; VIRUS LOAD; VIRUS MUTATION;

CLINICAL TRIALS, PHASE III AS TOPIC; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; HIV; HIV INFECTIONS; HIV INTEGRASE; HIV PROTEASE INHIBITORS; HUMANS; PYRROLIDINONES; QUINOLONES;

EID: 52149105352     PISSN: 14620308     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (16)

1. Bushman FD, Fujiwara T, Craigie R. Retroviral DNA integration directed by HIV integration protein in vitro. Science, 1990, 249, 1555-1558.
2. Grinsztejn B, Nguyen BY, Katlama C et al. Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial. Lancet, 2007, 369, 1261-1269.
3. Cooper DA, Gatell J, Rockstroh J et al. 48-week results from BENCHMRK-1, a phase III study or raltegravir in patients with failing antiretroviral therapy with triple-class resistant HIV-1. 15th Conference on Retroviruses and Opportunistic Infections, Boston, February 2008. Abstract 788.
4. Steigbigel R, Kumar P, Eron J et al. 48-week results from BENCHMRK-2, a phase III study or raltegravir in patients with failing antiretroviral therapy with triple-class resistant HIV-1. 15th Conference on Retroviruses and Opportunistic Infections, Boston, February 2008. Abstract 789.
5. Harris M, Larsen G, Montaner J. Outcomes of patients switched from enfuvirtide to raltegravir within a virologically suppressive regimen. 15th Conference on Retroviruses and Opportunistic Infections, Boston, February 2008. Abstract 799.
6. Talbot A, Marcotte S, Thomas R et al. Retrospective analysis of a switch from enfuvirtide to raltegravir in patients with undetectable viral load: efficacy at 12 weeks in a Montreal cohort. 17th Annual Canadian Conference on HIV/AIDS Research, Montreal, April 2008.
7. Markowitz M, Nguyen BY, Gotuzzo E et al. Rapid and durable antiretroviral effect of the HIV-1 integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: results of a 48-week controlled study. J Acquir Immune Defic Syndr 2007, 46, 125-133.
8. www.fda.gov/cder/foi/nda/2007/022145_ClinPharmR_P1.pdf accessed 24th June 2008.
9. Zolopa A, Mullen M, Berger D et al. The HIV integrase inhibitor GS-9137 demonstrates potent ARV activity in treatment-experienced patients. 14th Conference on Retroviruses and Opportunistic Infections, Los Angeles, February 2007. Abstract 143LB.
10. Zolopa AR, Lampiris H, Blick G et al. The HIV integrase inhibitor elvitegravir (EVG/r) has potent and durable activity in treatment-experienced patients with active optimized background therapy (OBT). 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, September 2007. Abstract H-714.
11. Cooper D, Gatell J, Rockstroh J et al. Results of BENCHMRK-1, a phase III study evaluating the efficacy and safety of MK-0518, a novel HIV-1 integrase inhibitor, in patients with triple-class resistant virus. 14th Conference on Retroviruses and Opportunistic Infections, Los Angeles, February 2007. Abstract 105aLB.
12. Steigbigel R, Kumar P, Eron J et al. Results of BENCHMRK-2, a phase III study evaluating the efficacy and safety of MK-0518, a novel HIV-1 integrase inhibitor, in patients with triple-class resistant virus. 14th Conference on Retroviruses and Opportunistic Infections, Los Angeles, February 2007. Abstract 105bLB.
13. Hazuda DJ, Miller MD, Nguyen BY, Zhao J for the P005 Study Team. Resistance to the HIV-integrase inhibitor raltegravir: analysis of protocol 005, a Phase II study in patients with triple-class resistant HIV-1 infection. 16th International HIV Drug Resistance Workshop, Barbados, June 2007. Abstract 8.
14. McColl DJ, Fransen S, Gupta S et al. Resistance and cross-resistance to first generation integrase inhibitors: insights from a phase II study of elvitegravir (GS-9137). 16th International HIV Drug Resistance Workshop, Barbados, June 2007. Abstract 9.
15. DeJesus E, Cohen C, Elion R et al. First report of raltegravir (RAL, MK-0518) use after virological rebound on elvitegravir (EVT, GS 9137). 4th International AIDS Society Conference on HIV Pathogenesis, Treatment, and Prevention, Sydney, July 2007. Abstract TUPEB032.
16. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. January 29, 2008; 1-128. Available at www.aidsinfo.nih.gov/ContentFiles/ AdultandAdolescentGL.pdf. Accessed 25th June 2008.